引用本文:刘艳杰,陆翰杰.白蛋白结合紫杉醇联合替吉奥治疗晚期胰腺癌的疗效及安全性观察[J].中国临床新医学,2019,12(9):997-1000.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 35次   下载 34 本文二维码信息
码上扫一扫!
分享到: 微信 更多
白蛋白结合紫杉醇联合替吉奥治疗晚期胰腺癌的疗效及安全性观察
刘艳杰,陆翰杰
471000 洛阳,郑州大学附属洛阳中心医院药物Ⅰ期临床试验研究室(刘艳杰),肿瘤内科(陆翰杰)
摘要:
[摘要] 目的 观察白蛋白结合紫杉醇联合替吉奥治疗晚期胰腺癌的疗效及安全性。方法 收集2015-06~2018-01该院收治的60例接受治疗的晚期胰腺癌患者的临床资料。按照随机数字表法分为观察组和对照组。观察组31例采用白蛋白结合紫杉醇联合替吉奥治疗,对照组29例采用吉西他滨联合替吉奥治疗,治疗2~6个周期,观察两组的临床效果及不良反应。结果 观察组的客观有效率(ORR)高于对照组(41.9% vs 20.7%),但差异无统计学意义(P>0.05)。观察组的疾病控制率(DCR)高于对照组(80.6% vs 55.2%),差异有统计学意义(P<0.05)。两组的中位总生存期分别为9.9个月和8.9个月,差异有统计学意义(P<0.05)。结论 白蛋白结合紫杉醇联合替吉奥治疗晚期胰腺癌具有良好的有效性和安全性。
关键词:  白蛋白结合紫杉醇  替吉奥  胰腺癌
DOI:10.3969/j.issn.1674-3806.2019.09.17
分类号:R 735.9
基金项目:
Clinical efficacy and safety of nab-paclitaxel combined with S-1 in treatment of advanced pancreatic cancer
LIU Yan-jie, LU Han-jie
Phase Ⅰ Clinical Drug Trial Laboratory, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471000, China
Abstract:
[Abstract] Objective To investigate the efficacy and safety of nab-paclitaxel combined with S-1(tegafur, gimeracil and oteracil) in treatment of advanced pancreatic cancer. Methods The clinical data of 60 patients receiving treatment for advanced pancreatic cancer in our hospital during June 2015 and January 2018 were retrospectively analyzed. The patients were divided into observation group and control group according to the method of randam number table. The observation group(n=31) received nab-paclitaxel combined with S-1 and the control group(n=29) was treated with gemcitabine and S-1 for 2 to 6 cycles. The clinical effects and adverse reactions were observed in the two groups. Results The objective response rate(ORR) of the observation group was higher than that of the control group(41.9% vs 20.7%), without a significant difference between the two groups(P>0.05). The disease control rate(DCR) of the observation group was higher than that of the control group(80.6% vs 55.2%), with a significant difference between the two groups(P<0.05). The median overall survival time was 9.9 months in the observation group and 8.9 months in the control group, with a significant difference between the two groups(P<0.05). Conclusion The combination of nab-paclitaxel and S-1 has good efficacy and safety in the treatment of advanced pancreatic cancer.
Key words:  Nab-paclitaxel  Tegafur, gimeracil and oteracil  Pancreatic cancer